Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amgen (AMGN)
NASDAQ:AMGN
Amgen (AMGN) Stock Price & Analysis
5,723 Followers
AMGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$211.82 - $326.12
Previous Close$310.77
Volume1.54M
Average Volume (3M)2.55M
Market Cap
$166.71B
Enterprise Value$221.02B
Total Cash (Recent Filing)$9.71B
Total Debt (Recent Filing)$64.02B
Price to Earnings (P/E)44.4
Beta0.46
Next Earnings
Aug 06, 2024EPS Estimate
$4.97Last Dividend Ex-Date
May 16, 2024Dividend Yield2.82%
Share Statistics
EPS (TTM)6.99
Shares Outstanding536,434,692
10 Day Avg. Volume2,426,082
30 Day Avg. Volume2,551,331
Standard Deviation0.07
R-Squared0.19
Alpha0.00792
Financial Highlights & Ratios
Price to Book (P/B)-3.68
Price to Sales (P/S)5.86
Price to Cash Flow (P/CF)60.00
P/FCF Ratio22.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.48
Enterprise Value/Gross Profit11.20
Enterprise Value/Ebitda18.15
Forecast
1Y Price Target
$322.25Price Target Upside3.69% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Amgen News
PremiumCompany Announcements
Amgen Shareholders Approve Equity Plan and Elect Directors
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Pipeline DevelopmentThe Ph3 trial of Uplizna in Immunoglobulin G4-related disease (IgG4-RD) showed an 87% reduction in risk of IgG4-RD flares vs. placebo and met all key secondary endpoints.
Market Expansion And OpportunitiesAMGN estimates that there are approx. 20-40K US patients with IgG4-RD, which could offer meaningful market expansion relative to NMOSD’s approx. 8K addressable US patients.
Technology And InnovationAMGN has been investing in technology and artificial intelligence for over 5 years and is already seeing returns.
Bears Say
Clinical TrialsTezspire induced a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations versus placebo, which was not statistically significant.
Financial PerformanceProduct sales came in about $100MM light driven by weak Enbrel, Neulasta, Nplate, Otezla, Tepezza and offset by Repatha.
Operational ChallengesAmgen confirmed cybersecurity issues in February and March significantly impacted Otezla prescriptions.
---
Ownership Overview
1.08% Insiders
22.91% Mutual Funds
26.12% Other Institutional Investors
49.88% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
AMGN FAQ
What was Amgen’s price range in the past 12 months?
Amgen lowest stock price was $211.82 and its highest was $326.12 in the past 12 months.
What is Amgen’s market cap?
Currently, no data Available
When is Amgen’s upcoming earnings report date?
Amgen’s upcoming earnings report date is Aug 06, 2024 which is in 34 days.
How were Amgen’s earnings last quarter?
Amgen released its earnings results on May 02, 2024. The company reported $3.96 earnings per share for the quarter, beating the consensus estimate of $3.879 by $0.081.
Is Amgen overvalued?
According to Wall Street analysts Amgen’s price is currently Undervalued.
Does Amgen pay dividends?
Amgen pays a Quarterly dividend of $2.25 which represents an annual dividend yield of 2.82%. See more information on Amgen dividends here
What is Amgen’s EPS estimate?
Amgen’s EPS estimate is $4.97.
How many shares outstanding does Amgen have?
Amgen has 536,434,700 shares outstanding.
What happened to Amgen’s price movement after its last earnings report?
Amgen reported an EPS of $3.96 in its last earnings report, beating expectations of $3.879. Following the earnings report the stock price went up 11.815%.
Which hedge fund is a major shareholder of Amgen?
Among the largest hedge funds holding Amgen’s share is PRIMECAP Management Co. It holds Amgen’s shares valued at 4B.
---
Amgen Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$322.25 (3.69% Upside)
$322.25 (3.69% Upside)
Blogger Sentiment
Bullish
AMGN Sentiment 89%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 93.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
44.34%
12-Months-Change
Fundamentals
Return on Equity
72.57%
Trailing 12-Months
Asset Growth
4.80%
Trailing 12-Months
Company Description
Amgen
Founded in 1980, California-based Amgen, Inc. is one of the world's leading biotechnology companies, which is engaged in the discovery, development, manufacture and marketing of human therapeutics. It primarily focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience areas.
---
AMGN Company Deck
---
AMGN Earnings Call
Q1 2024
0:00 / 0:00
---
AMGN Revenue Breakdown
14.36% Prolia
13.11% Enbrel
7.76% Otezla
7.49% XGEVA
57.27% Other
---
AMGN Stock 12 Month Forecast
Average Price Target
$322.25
▲(3.69% Upside)
Technical Analysis
Best Analysts Covering AMGN
1 Year
1 Year Success Rate
24/28 ratings generated profit
1 Year Average Return
+16.68%
reiterated a buy rating last month
Copying Yaron Werber's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +16.68% per trade.
---